274 related articles for article (PubMed ID: 25625346)
1. Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine.
Narita M; Kanda T; Abe T; Uchiyama T; Iwafuchi M; Zheng Z; Liu A; Kaifu T; Kosugi S; Minagawa M; Itoh K; Takahashi M
Int J Oncol; 2015 Apr; 46(4):1699-709. PubMed ID: 25625346
[TBL] [Abstract][Full Text] [Related]
2. Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA.
Narita M; Tochiki N; Saitoh A; Watanabe N; Kaji M; Satoh N; Yamahira A; Nakamura T; Masuko M; Furukawa T; Toba K; Fuse I; Aizawa Y; Takahashi M
Med Oncol; 2009 Dec; 26(4):429-36. PubMed ID: 19058036
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma.
Iwahashi M; Katsuda M; Nakamori M; Nakamura M; Naka T; Ojima T; Iida T; Yamaue H
Cancer Sci; 2010 Dec; 101(12):2510-7. PubMed ID: 20874827
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
5. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.
Kono K; Mizukami Y; Daigo Y; Takano A; Masuda K; Yoshida K; Tsunoda T; Kawaguchi Y; Nakamura Y; Fujii H
Cancer Sci; 2009 Aug; 100(8):1502-9. PubMed ID: 19459850
[TBL] [Abstract][Full Text] [Related]
7. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.
Romano E; Rossi M; Ratzinger G; de Cos MA; Chung DJ; Panageas KS; Wolchok JD; Houghton AN; Chapman PB; Heller G; Yuan J; Young JW
Clin Cancer Res; 2011 Apr; 17(7):1984-97. PubMed ID: 21355077
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.
Höltl L; Ramoner R; Zelle-Rieser C; Gander H; Putz T; Papesh C; Nussbaumer W; Falkensammer C; Bartsch G; Thurnher M
Cancer Immunol Immunother; 2005 Jul; 54(7):663-70. PubMed ID: 15918076
[TBL] [Abstract][Full Text] [Related]
10. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H
Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2020 Oct; 24(5):482-491. PubMed ID: 32524770
[TBL] [Abstract][Full Text] [Related]
12. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268
[TBL] [Abstract][Full Text] [Related]
13. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
17. Induction of cytotoxic T lymphocytes primed with tumor RNA-loaded dendritic cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design.
Gholamin M; Moaven O; Farshchian M; Mahmoudi M; Sankian M; Memar B; Forghani MN; Malekzadeh R; Rajabi-Mashhadi MT; Abbaszadegan MR
BMC Cancer; 2010 Jun; 10():261. PubMed ID: 20525404
[TBL] [Abstract][Full Text] [Related]
18. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors.
Toungouz M; Libin M; Bulté F; Faid L; Lehmann F; Duriau D; Laporte M; Gangji D; Bruyns C; Lambermont M; Goldman M; Velu T
J Leukoc Biol; 2001 Jun; 69(6):937-43. PubMed ID: 11404379
[TBL] [Abstract][Full Text] [Related]
19. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
Lesterhuis WJ; Schreibelt G; Scharenborg NM; Brouwer HM; Gerritsen MJ; Croockewit S; Coulie PG; Torensma R; Adema GJ; Figdor CG; de Vries IJ; Punt CJ
Cancer Immunol Immunother; 2011 Feb; 60(2):249-60. PubMed ID: 21069321
[TBL] [Abstract][Full Text] [Related]
20. Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
Shintaku I; Kawagoe N; Yutani S; Hoshi S; Orikasa S; Yoshizumi O; Itoh K
Urol Res; 2000 Jun; 28(3):178-84. PubMed ID: 10929426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
